Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQ05105 in Myeloproliferative Neoplasms
NCT04339400Phase 1Completed
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Nov 2018
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of rovadicitinib in myeloproliferative neoplasms (MPN), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoints: Dose Limiting Toxicity at 28 days and Maximal tolerance dose at 28 days. Started Nov 2018; status: completed.
02
Drugs
rovadicitinib
03
Conditions
myeloproliferative neoplasms (MPN)
Beyond the preview
Go deeper on NCT04339400.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04339400.